Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus
Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated
Lymphoid Tissue (MALT) lymphoma presenting with measurable disease.